Skip to content
Search

Latest Stories

Covid-19 prevalence high but growth slowing in England, Imperial College study says

The prevalence of Covid-19 infections in England is much higher than it was at the end of August but there are signs that growth in infection rate is slowing, a study by Imperial College said today (Oct 1).

The findings come after Prime Minister Boris Johnson pleaded with Britons to obey the rules imposed to tackle a rapidly accelerating second wave of the coronavirus, with more than 7,000 new cases of Covid-19 reported in each of the last two days.


The Imperial study showed one in 200 people were infected, but also that the reproduction R rate dropped from 1.7 to 1.1, meaning that on average, 10 infected people will go on to infect another 11 people rather than 17 people.

The fall in the R number therefore implies the epidemic’s growth might be decelerating.

“While our latest findings show some early evidence that the growth of new cases may have slowed, suggesting efforts to control the infection are working, the prevalence of infection is the highest that we have recorded to date,” Imperial’s Professor Paul Elliott said.

The study, the largest of its kind in the country, tested 84,610 volunteers between Sept. 18 and 26.

Of those, 363 tested positive, which is 55 people per 10,000 - and an increase on the 13 per 10,000 people found to be infected in the previous study between Aug. 24 and Sept. 7.

The latest study implied 411,000 people had the coronavirus, with prevalence increasing in all age groups.

Half of the volunteers did not have symptoms at the time of testing or the week before, but not all of those people remained asymptomatic throughout, the study said.

More For You

GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less
Community Pharmacy Scotland secures £10m reimbursement uplift amid ongoing negotiations

Negotiations continue on the Global Sum element of remuneration.

Getty Images

Community Pharmacy Scotland secures £120m reimbursement deal for 2025/26

Community Pharmacy Scotland (CPS) has accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

The agreement marks the first phase of ongoing negotiations surrounding community pharmacy funding for the upcoming financial year.

Keep ReadingShow less